EMA Authorised: Votrient (pazopanib) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised pazopanib (Votrient) for renal cell carcinoma in the European Union. The Marketing Authorization Holder is Novartis Europharm Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Votrient (Pazopanib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Renal Cell. MAH: Novartis Europharm Limited. Decision date: 28/10/2025